These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29503845)

  • 1. Evaluation of agonist and antagonist radioligands for somatostatin receptor imaging of breast cancer using positron emission tomography.
    Dude I; Zhang Z; Rousseau J; Hundal-Jabal N; Colpo N; Merkens H; Lin KS; Bénard F
    EJNMMI Radiopharm Chem; 2017; 2(1):4. PubMed ID: 29503845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging of [52 Mn]Mn-DOTATATE and [52 Mn]Mn-DOTA-JR11.
    Omweri JM; Houson HA; Lynch SE; Tekin V; Sorace AG; Lapi SE
    Res Sq; 2024 Aug; ():. PubMed ID: 39149492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparison of [
    Ahenkorah S; Cawthorne C; Murce E; Deroose CM; Cardinaels T; Seimbille Y; Bormans G; Ooms M; Cleeren F
    Nucl Med Biol; 2023; 118-119():108338. PubMed ID: 37018875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal Imaging of 2-Cycle PRRT with
    Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
    J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
    Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
    J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
    Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin Receptor Antagonists for Imaging and Therapy.
    Fani M; Nicolas GP; Wild D
    J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
    Fani M; Braun F; Waser B; Beetschen K; Cescato R; Erchegyi J; Rivier JE; Weber WA; Maecke HR; Reubi JC
    J Nucl Med; 2012 Sep; 53(9):1481-9. PubMed ID: 22851637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.
    Liu M; Cheng Y; Bai C; Zhao H; Jia R; Chen J; Zhu W; Huo L
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2002-2011. PubMed ID: 38337073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-Head Comparison of
    Lin Z; Zhu W; Zhang J; Miao W; Yao S; Huo L
    J Nucl Med; 2023 Sep; 64(9):1406-1411. PubMed ID: 37474267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
    Dalm SU; Haeck J; Doeswijk GN; de Blois E; de Jong M; van Deurzen CHM
    J Nucl Med; 2017 Oct; 58(10):1609-1614. PubMed ID: 28450563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate.
    Ma MT; Cullinane C; Waldeck K; Roselt P; Hicks RJ; Blower PJ
    EJNMMI Res; 2015 Dec; 5(1):52. PubMed ID: 26452495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
    Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR
    PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution and radiation dose estimates for
    Krebs S; Pandit-Taskar N; Reidy D; Beattie BJ; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; O'Donoghue JA
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):677-685. PubMed ID: 30374529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-Head Comparison of
    Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
    J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
    [No Abstract]   [Full Text] [Related]  

  • 18. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of
    Zhu W; Jia R; Yang Q; Cheng Y; Zhao H; Bai C; Xu J; Yao S; Huo L
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1613-1622. PubMed ID: 34874478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution, Pharmacokinetics, and Dosimetry of
    Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
    J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.